Which Is the Better Small-Cap ETF, Schwab's SCHA or iShares' IJR?

The Schwab U.S. Small-Cap ETF (SCHA) offers broader small-cap exposure with 1,727 stocks versus iShares’ 652 holdings, while charging a lower 0.03% expense ratio (half of iShares’ 0.06%). Performance is also stronger over the trailing year (SCHA +34.2% vs IJR +29.9%) with similar dividend yields (1.00% vs 1.10%). The trade-off is higher volatility for SCHA (5-year max drawdown -30.8% vs -28.0%), but it is positioned as a cost-effective, long-term “set-it-and-forget-it” option.

Analysis

This is a fee-and-factor story more than a fundamental one: the economic edge from 3 bps is real, but it matters only if the ETF becomes a meaningful default sleeve in model portfolios and brokerage platforms. In the near term, the lower-cost, broader basket should benefit from incremental retail and robo flows, while the more selective vehicle retains an edge with institutions that care about liquidity, tighter spreads, and cleaner profitability exposure.

The second-order read is that SCHA is the higher-beta expression of a small-cap rebound: more sensitivity to rates, credit easing, and speculative breadth, but also more exposure to cash-burning names that get punished if refinancing conditions tighten. That makes names like LITE, RVMD, and SNDK the incremental beneficiaries of “anything small-cap” flows, while MOH and BTSG are the relatively defensive anchors in the more quality-screened basket. If the market regime shifts back toward risk-off, the broader basket should underperform on drawdown and funding-risk convexity.

The contrarian point is that investors may be overestimating how much fee compression alone can change AUM leadership; IJR’s liquidity and index credibility are harder to displace than a 3 bps pricing advantage. The real catalyst is not the article itself but whether small-cap breadth improves enough for passive inflows to amplify performance relative to large-cap growth. If 10-year yields back up or credit spreads widen, the lower-quality tail inside the broader fund becomes a hidden drag within weeks, not months.

Key Decisions for Investors

• Prefer IJR over SCHA for core small-cap exposure in risk-off or late-cycle tapes; the liquidity and profitability screen should outperform if credit spreads widen over the next 1-3 months. Falsifier: sustained outperformance of the broad small-cap basket by >3-4% with stable spreads.
• Use SCHA only as a tactical beta vehicle if the desk wants a high-conviction small-cap risk-on expression tied to easing rates; consider pairing long SCHA / short IJR for 6-12 months if ETF flow data shows fee-led share gains. Stop if IJR keeps capturing the majority of new small-cap ETF inflows.
• Watch LITE, RVMD, and SNDK as higher-convexity beneficiaries of broad small-cap inflows; these are the names most likely to see multiple expansion if breadth improves over the next quarter. Falsifier: any reset in financing conditions or weak forward guidance.
• Avoid forcing a directional trade in BTSG or MOH off this article alone; they are more likely to behave as relative defensives inside the small-cap complex than as standalone alpha. Reassess only if small-cap liquidity or healthcare reimbursement data becomes the actual driver.
• Set an alert on IWM / small-cap credit proxies rather than the ETFs themselves: if Russell 2000 relative strength improves while HY spreads tighten, SCHA’s broader exposure should outperform IJR over 1-3 months; if not, stay with IJR or no trade.